Prescription Drug Supply Chain Pricing Transparency Act
Sponsored By: Senator Michael Bennet
Introduced
Summary
This bill would require the Government Accountability Office to study how price-related compensation structures operate across the retail prescription drug supply chain. It aims to map who gets fees tied to a drug's price and how those payments could affect drug selection and distribution.
Show full summary
- Congress and oversight bodies would receive a comprehensive GAO report with recommendations within 2 years.
- Pharmacy benefit managers, Part D plan sponsors, drug wholesalers, pharmacies, manufacturers, pharmacy services administrative organizations, brokers, auditors, consultants, rebate aggregators, and other service providers would be examined for the types, magnitudes, and prevalence of price-linked fees.
- The study would cover business models, differences between affiliated and unaffiliated entities, potential conflicts of interest such as percentage-based fees that could favor higher-priced drugs, trends over time, and comparisons across market segments like Medicare Part D and Medicaid.
Your PRIA Score
Personalized for You
How does this bill affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this bill and every other piece of legislation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Bill Overview
No Economic Impacts Identified for this Bill
Sponsors & CoSponsors
Sponsor
Michael Bennet
CO • D
Cosponsors
James Lankford
OK • R
Sponsored 1/29/2026
Roll Call Votes
No roll call votes available for this bill.
View on Congress.govTake It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in